Zosano pharma corp (ZSAN)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities
Net loss

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from operating activities:
Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-28,714

-29,832

-29,729

-30,900

-31,959

-28,427

-25,058

-20,122

-16,452

-14,241

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

2,579

2,559

2,549

2,543

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

1,615

1,612

1,533

1,456

1,400

1,178

945

745

598

692

834

919

1,089

1,168

0

0

0

-

-

-

-

-

-

-

-

Change in operating lease right-of-use assets

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

691

683

668

734

734

764

0

0

0

-

-

-

-

-

-

-

-

-

2,599

2,790

2,913

3,042

0

0

0

Effective interest on financing obligations

0

-

-

-

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Capitalized effective interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Accretion of interest on marketable securities

0

-

-

-

0

-

-

-

28

-2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt (premium) issuance cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Accretion of interest payment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

Revaluation of warrants to fair value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-48

137

137

137

185

0

0

0

Deferred rent

-

-

-

-

-

-936

-1,198

-883

-757

-443

-271

-75

-1

-6

-12

-17

-21

52

126

199

271

265

0

0

0

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

653

431

304

160

184

0

0

0

Loss on debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Change in operating assets and liabilities
Accounts receivable from joint venture partner

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,426

0

0

0

Prepaid expenses and other assets

92

193

-292

84

-1,390

-1,208

-408

-512

1,152

1,279

1,258

895

-694

36

1,240

996

1,019

222

-2,260

-1,010

648

-154

0

0

0

Accounts payable

493

1,764

1,490

118

-157

98

30

817

1,413

-34

-682

258

-561

172

619

52

784

724

-39

-132

-800

-2,631

0

0

0

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Accrued compensation and other accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

Accrued compensation and other accrued liabilities

0

-

0

0

0

-

0

0

0

-

-278

-168

507

72

816

745

1,112

38

-694

-891

-399

-1,118

0

0

0

Operating lease liabilities

-1,010

-963

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-170

-306

-482

-682

-955

0

0

0

Net cash used in operating activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

0

0

-

-

-

-24,322

-25,686

-25,429

-26,916

-27,068

-24,155

-19,444

-15,959

-13,968

-10,915

0

0

0

Cash flows from investing activities
Proceeds from maturities of marketable securities

8,400

17,400

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-30

0

0

0

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

-

0

-

-

-

-

30,208

0

0

0

-

-

-

0

-

-

-

-

Purchases of property and equipment

9,128

11,760

12,347

9,597

9,055

5,490

4,617

2,725

1,618

1,244

0

0

0

-

566

644

577

432

288

554

804

1,176

0

0

0

Increase in other investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-63

21

19

22

28

0

0

0

-

-

-

-

Increase in investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

0

0

-

-

-

21,941

30,272

34,448

28,911

-22,625

-30,946

-39,444

-43,187

-769

-1,133

0

0

0

Net cash (used in) provided by investing activities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows used in financing activities
Cash flows from financing activities:
Proceeds from offering of securities, net of costs

-

-

-

-

-

-

-

-

-

26,623

26,623

26,623

26,623

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of Series C warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,475

14,475

0

0

0

0

Principal payments on financing obligations

3,668

3,079

2,686

5,150

5,985

6,999

7,894

6,045

5,925

5,808

5,822

5,722

4,286

2,876

1,364

0

11,117

11,465

11,465

11,465

348

0

0

0

0

Proceeds from exercise of warrants and issuance of common stock

-

-

-

-

-

-

-

-

-

4,041

4,041

4,041

4,041

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

5

6

36

36

37

73

45

40

38

0

0

0

Proceeds from borrowing under related parties bridge notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,833

0

0

0

Proceeds from initial public offering of securities, net of underwriting commissions and discounts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

47,140

47,140

47,140

47,140

0

0

0

0

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,359

1,801

1,767

1,514

442

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

33,161

3,771

5,284

2

337

60,533

61,460

61,466

65,046

7,349

0

0

0

Net cash provided by (used in) financing activities

52,411

29,829

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

12,415

-2,824

-5,470

-1,945

2,605

-2,511

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents, and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

8,357

14,303

1,997

-49,356

5,432

2,572

2,320

50,309

-4,699

0

0

0

Supplemental cash flow information
Cash paid for interest

903

834

1,207

1,046

953

884

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

1,096

1,166

1,203

1,164

3,774

3,591

3,533

3,276

361

243

0

0

0

Non-cash investing and financing activities:
Acquisition of property and equipment under accounts payable and other accrued liabilities

8,747

4,420

6,945

8,905

7,286

3,374

99

401

468

144

109

71

80

64

0

0

0

-

-

-

-

-

-

-

-

Conversion of debt to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,407

7,407

7,407

7,407

0

0

0

0

Accrued deferred offering cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Unpaid offering costs

202

188

107

44

-179

0

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

0

0

0

Right-of-use assets acquired under finance lease obligations

0

22

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of warrant liability to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

252

0

0

0

-

-

-

-

Reclassification of warrant liability to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Registered Direct Offering
Proceeds from offering of securities, net of costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public Stock Offering
Proceeds from offering of securities, net of costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

At-the-market Offering
Proceeds from offering of securities, net of costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-